Andrew Donati, MD
Nephrology · Waterbury, CTNPI 1730543653
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.
Across 159 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$453
- Bayer$416
- AstraZeneca$372
- Travere Therapeutics, Inc.$284
- Novartis$253
- Boehringer Ingelheim$214
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,24891%
- Education$3059%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 12 | $453 |
| Bayer | 21 | $416 |
| AstraZeneca(2 entities) | 18 | $372 |
| Travere Therapeutics, Inc. | 19 | $284 |
| Novartis | 12 | $253 |
| Boehringer Ingelheim | 8 | $214 |
| Amgen(2 entities) | 6 | $149 |
| Xeris Pharmaceuticals, Inc. | 6 | $141 |
| Otsuka America Pharmaceutical, Inc. | 5 | $119 |
| Novo Nordisk | 5 | $114 |
| Vifor Pharma, Inc. | 5 | $107 |
| Akebia Therapeutics Inc | 4 | $97 |
| Calliditas Therapeutics US Inc. | 5 | $97 |
| Pfizer | 4 | $88 |
| Aurinia Pharma U.S., Inc. | 3 | $77 |
| GSK | 4 | $76 |
| ANI Pharmaceuticals, Inc. | 2 | $65 |
| Baxter Healthcare | 3 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $55 |
| Sanofi | 2 | $49 |
| Ardelyx, Inc. | 2 | $48 |
| OPKO Pharmaceuticals, LLC | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Nxstage Medical, Inc. | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $15 |
How this compares
$3,554 in reported general payments places this provider in the 75th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 71 | $74,085 |
| JardianceEmpagliflozin | 29 | $38,873 |
| RybelsusSemaglutide | 12 | $11,433 |
| EliquisApixaban | 11 | $10,842 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,465 |
| Sevelamer Carbonate | 41 | $6,702 |
| Calcitriol | 53 | $1,204 |
| Losartan Potassium | 210 | $1,180 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 44 | $1,062 |
| Labetalol Hcl | 19 | $949 |
| Torsemide | 61 | $843 |
| Olmesartan Medoxomil | 74 | $819 |
| Nifedipine ErNifedipine | 28 | $679 |
| Tamsulosin Hcl | 28 | $677 |
| Carvedilol | 143 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $372 | $74,08571 claims |
| Boehringer IngelheimJardiance | $214 | $38,87329 claims |
| Novo NordiskRybelsus | $114 | $11,43312 claims |
| PfizerEliquis | $88 | $10,84211 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $65 | $38418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Waterbury
- Marc CiampiWaterbury$16K
- Sandeep TiyyaguraWaterbury$5K
- Anthony CusanoWaterbury$3K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.